Rom S. Leidner

机构：Providence Portland Medical Center · ORCID：0000-0003-0788-7938

发表论文 233 篇 · 总被引 6432 次 · h-index 34

代表论文

• Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial (2025 · Nature Medicine · 被引 115)
• Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (2025 · Journal for ImmunoTherapy of Cancer · 被引 12)
• Widespread Adoption of Precision Anticancer Therapies After Implementation of Pathologist-Directed Comprehensive Genomic Profiling Across a Large US Health System (2024 · JCO Oncology Practice · 被引 12)
• TRIALSCOPE — A Framework for Clinical Trial Simulation from Real-World Data (2025 · NEJM AI · 被引 11)
• AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8α/β coreceptor, and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors. (2024 · Journal of Clinical Oncology · 被引 9)
• Approaches to overcome the current treatment plateau in immunotherapy (2025 · European Journal of Cancer · 被引 5)